- Home
- OXSQ vs TVRD Comparison
OXSQ vs TVRD Comparison
Compare OXSQ & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXSQ | TVRD |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.4M | 246.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OXSQ | TVRD |
|---|---|---|
| Price | $1.85 | $4.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 641.5K | 123.7K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 22.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,142,565.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $3.74 |
| 52 Week High | $2.87 | $43.65 |
Technical Indicators
Market Signals| Indicator | OXSQ | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 34.35 |
| Support Level | $1.82 | $4.05 |
| Resistance Level | $1.87 | $4.71 |
| Average True Range (ATR) | 0.03 | 0.27 |
| MACD | -0.00 | 0.55 |
| Stochastic Oscillator | 75.00 | 73.20 |
Price Performance
Historical ComparisonAbout OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.